Vigil Neuroscience’s Oral Alzheimer’s Candidate VG-3927 Shows Promising Phase 1 Results with Sanofi’s Strategic Support

VG-3927 Phase 1 Success:
Vigil Neuroscience has reported positive data from its Phase 1 clinical trial evaluating VG-3927, a potential once-daily oral therapy for Alzheimer’s disease (AD). The trial demonstrated a favorable safety and tolerability profile, robust and dose-dependent reductions of sTREM2, and sustained functional target engagement15.

Sanofi Strategic Investment:
Sanofi has made a $40 million strategic investment in Vigil Neuroscience, providing an exclusive right of first negotiation for the license of Vigil's small molecule TREM2 agonist program, including VG-3927. This investment extends Vigil's cash runway into 202623.

Phase 2 Plans:
Vigil plans to advance VG-3927 into a Phase 2 trial in the third quarter of 2025, selecting a 25mg QD oral dose that fully engages the desired pharmacology5.

Clinical and Preclinical Data:
Combined clinical and preclinical data confirm that VG-3927 elicits neuroprotective activation of microglia downstream of TREM2 signaling. The PK and sTREM2 reduction observed in the AD cohort was consistent with healthy volunteers and similar across evaluated TREM2 and ApoE genetic variants5.

Future Presentations:
Vigil expects to provide additional data in an oral presentation at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Disease in April 20255.

Sources:

1. https://investors.vigilneuro.com/news-releases/news-release-details/vigil-neuroscience-announces-interim-data-its-ongoing-phase-1

2. https://investors.vigilneuro.com/news-releases/news-release-details/vigil-neuroscience-announces-40-million-strategic-investment

3. https://www.stocktitan.net/news/VIGL/vigil-neuroscience-announces-40-million-strategic-investment-from-dafvpj7bdgif.html

5. https://investors.vigilneuro.com/news-releases/news-release-details/vigil-neuroscience-reports-positive-data-its-phase-1-clinical